Why the study?
Up to one-third of patients referred for TTVI have a transvalvular PPM or ICD lead, posing complex decision-making regarding potential lead interactions and the risk of jailing or lead damage.
This scientific statement provides guidance for the complex decision-making required when performing transcatheter tricuspid valve interventions in patients with existing transvalvular pacemaker or ICD leads.
Answers are grounded in this paper and cite their sources.
Gives Heart Teams a shared framework for lead management at TTVI; leaves open extract-versus-jail outcomes pending prospective data.
Up to one-third of patients referred for transcatheter tricuspid valve intervention (TTVI) have a transvalvular pacemaker (PPM) or implantable cardioverter-defibrillator (ICD) lead in place. Both the electrophysiology and interventional cardiology communities have been alerted to the complexity of decision-making in this situation due to potential interactions between the leads and the TTVI material, including the risk of jailing or damage to the leads. This document, commissioned by the European Heart Rhythm Association and the European Association of Percutaneous Cardiovascular Interventions of the ESC, reviews the scientific evidence to inform Heart Team discussions on the management of patients with a PPM or ICD who are scheduled for or have undergone TTVI.
No takes yet. Share an insight, caveat, or question.
Deharo et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: